NXP001 (Oncology) – Exercise of Option by Oxilio

Cambridge, UK - 22nd March 2021

London, UK – 22 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that Oxilio Ltd (“Oxilio”) has exercised its option to acquire a licence for NXP001 (a proprietary new form of aprepitant) for oncology indications.

Download News

Back to all News